A novel and proprietary way to reprogram and boost the patient’s own immune system for fighting cancer

MaxiVAX novel anti-cancer therapy is revolutionary by the fact that it is based on triggering the patient’s own natural immune response mechanism via an innovative and proprietary technology in order to eliminate the deadly cancer cells. In principle all types of cancer can be addressed, including blood related cancers.

MVX-ONCO-1 consists of a very small device, which is placed underneath the skin with a little incision requiring only one suture and is composed of: 

  1. Irradiated tumour cells from the patient, placed next to the device as the target for the immune response.
  2. A strong immune-booster (GM-CSF: granulocyte-macrophage colony stimulating factor), released from an encapsulated, genetically modified cell line

The two main advantages of this approach is that all antigens of the cancer are targeted and that the immune-booster is delivered continuously over a one-week period instead of a bolus injection.

Detailed information related to MVX-ONCO-1 is available on request.


Capsules loaded with cells capable of manufacturing and releasing locally a substance of medical benefit have being pioneered by Patrick Aebischer. These cells, being protected by the capsule from elimination by the patient’s immune response, can thus produce locally the substance of interest locally for several weeks. This technology has been adapted and used by MaxiVAX for the sustained production of the immune-boosting protein GM-CSF at the site of vaccination with appropriate antigens. Inside the human body, GM-CSF is a rather unstable protein with a half-life of only a few hours and has thus to be produced in situ continuously in order to be therapeutically effective. A local and sustained delivery of GM-CSF is thus an optimal use of the technology of protein release via encapsulated cells, and unique to MaxiVAX in the field of Immuno-Oncology.